A 10-year follow-up analysis based on one of cardiology's most influential trials has shed further light on one of its key issues: how to sharpen selection of patients most likely to benefit from a ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Better imaging ...

A scorecard of four risk factors can help clinicians determine which patients with nonischemic cardiomyopathy would benefit from an implantable cardioverter defibrillator, researchers have found. The ...

Please provide your email address to receive an email when new articles are posted on . Among patients with nonischemic cardiomyopathy, women were less likely to die or have a ventricular event than ...

Major adverse events remained common in patients with nonischemic cardiomyopathy implanted with an electronic device. Women and those who received cardiac resynchronization therapy had better outcomes ...

SAN DIEGO, CA—The observational BIO-LIBRA study, which enrolled nearly 50% women, has revealed important outcome differences by both sex and device type among patients with nonischemic cardiomyopathy ...